A leukemia’s past shapes how it responds to therapy

We study the origins and biology of acute myeloid leukemia (AML), using immune therapies as a lens to reveal the programs AML cells inherit from normal blood development.

What we study

Lineage memory in AML

How an AML cell’s history as a myeloid-skewed progenitor shapes its behavior as a cancer cell.

Leukemia–immune crosstalk

How AML cells read signals from T cells and immune therapies, and what that reveals about treatment response.

Therapies that overcome resistance

Rational combinations and new immune therapies designed around the resistance AML biology encodes.

AML blasts retain lineage-encoded responses to myeloid growth factors like GM-CSF and IL-3. Because activated T cells make these cytokines, AML cells can use signals from CAR T cells to survive and resist immune killing.